And then theres this: While berberine isnt a GLP-1 receptor antagonist like semaglutide, it may promote GLP-1 production, according to a small 2021 mouse study (4)
In a SELECT trial involving 17,604 patients with a BMI of 27 or higher and preexisting cardiovascular disease, but without diabetes, weekly subcutaneous semaglutide reduced the risk of composite death by cardiovascular events by 20% [43]
But what if youre not ready for injections
Zepbound and Ozempic are exceptional in managing hunger signals, Wegovy excels in inducing feelings of fullness, and Mounjaro shines in boosting metabolism
Since the study is retrospective, which means it relies on information from events that have already occurred, it might contain more biases compared to a randomized control trial, he said
It works by signaling your brain that youre full and satisfied, even with smaller portions